Sartorius Stedim Biotech Statement on Share Capital

On December 3, 2024, Sartorius Stedim Biotech SA published a regulatory statement regarding the number of shares and voting rights comprising its share capital. This report, transmitted by EQS Group, is the responsibility of the issuer based in Aubagne, France. In accordance with Article L 233-8-II of the French Commercial Code and Article 223-6 of the AMF General Regulation, Sartorius Stedim Biotech has specified the stop figures as of November 30, 2024.

As of this specific date, the total number of shares comprising the share capital amounts to 97,330,405. The total number of theoretical voting rights, including treasury shares held by the company, is 165,567,769, while the number of net voting rights reaches 165,528,938. This declaration falls under the AMF category relating to the total number of voting rights and shares.